Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Bevacizumab + chemotherapy** refers to the combination of the anti-angiogenic monoclonal antibody bevacizumab with one or more cytotoxic chemotherapy agents. Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thereby starving tumors of necessary blood supply. When combined with chemotherapy, this regimen provides additive or synergistic anti-tumor effects. These combinations are commonly used in the treatment of multiple cancers, including metastatic colorectal cancer, ovarian cancer, cervical cancer, non-small cell lung cancer, and others. The specific chemotherapy agents vary by indication (e.g., FOLFIRI, carboplatin/paclitaxel).
- Brand names
- AvastinMVASIZirabev
- Other names
- FOLFIRI-BEVACIZUMAB
02
Targets
Beyond the preview
Go deeper on bevacizumab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + chemotherapy.